Open Access
Issue
Med Sci (Paris)
Volume 37, Number 6-7, Juin-Juillet 2021
Page(s) 593 - 600
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2021095
Published online 28 June 2021
  1. Camilleri M. Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. Clin Gastroenterol Hepatol 2015; 13 : 1051–7; quiz e61–2. [Google Scholar]
  2. Pereira FC, Berry D. Microbial nutrient niches in the gut. Environ Microbiol 2017 ; 19 : 1366–1378. [Google Scholar]
  3. Marteau P, Doré J. Le microbiote intestinal, un organe à part entière. Paris: John Libbey Eurotext, 2017, 338 p [Google Scholar]
  4. Normand S, Secher T, Chamaillard M. La dysbiose, une nouvelle entité en médecine ?. Med Sci (Paris) 2013 ; 29 : 586–589. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  5. Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016 ; 2 : 16014. [Google Scholar]
  6. Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 2017; 6. [Google Scholar]
  7. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014 ; 6 : 71–80. [Google Scholar]
  8. Kim YS, Kim N. Sex-gender differences in irritable bowel syndrome. J Neurogastroenterol Motil 2018 ; 24 : 544–558. [Google Scholar]
  9. Kamm MA, Farthing MJ, Lennard-Jones JE. Bowel function and transit rate during the menstrual cycle. Gut 1989 ; 30 : 605–608. [Google Scholar]
  10. Van der Giessen J, van der Woude CJ, Peppelenbosch MP, Fuhler GM. A direct effect of sex hormones on epithelial barrier function in inflammatory bowel disease models. Cells 2019; 8. [Google Scholar]
  11. Pietrzak A, Skrzydlo-Radomanska B, Mulak A, et al. Guidelines on the management of irritable bowel syndrome: in memory of Professor Witold Bartnik. Prz Gastroenterol 2018 ; 13 : 259–288. [Google Scholar]
  12. Chang L, Heitkemper MM, Wiley JW, Camilleri M. 2015 James W. Freston single topic conference: a renaissance in the understanding and management of irritable bowel syndrome. Gastroenterology 2016 ; 151 : e1–e8. [Google Scholar]
  13. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002 ; 51(suppl 1): i67–i71. [Google Scholar]
  14. Zhou Q, Verne GN. New insights into visceral hypersensitivity: clinical implications in IBS. Nat Rev Gastroenterol Hepatol 2011 ; 8 : 349–355. [Google Scholar]
  15. Camilleri M. Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. J Physiol 2014 ; 592 : 2967–2980. [Google Scholar]
  16. Turcotte JF, Kao D, Mah SJ, et al. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc 2013 ; 77 : 624–630. [Google Scholar]
  17. Martinez C, Rodino-Janeiro BK, Lobo B, et al. miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. Gut 2017 ; 66 : 1537–1538. [Google Scholar]
  18. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007 ; 449 : 804–810. [Google Scholar]
  19. Matsumoto H, Shiotani A, Katsumata R, et al. Mucosa-associated microbiota in patients with irritable bowel syndrome: a comparison of subtypes. Digestion 2021; 102 : 49–56. [Google Scholar]
  20. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24 : 521–30-e248. [Google Scholar]
  21. Maharshak N, Ringel Y, Katibian D, et al. Fecal and mucosa-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 2018 ; 63 : 1890–1899. [Google Scholar]
  22. Zhuang X, Tian Z, Li L, et al. Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol 2018 ; 9 : 1600. [Google Scholar]
  23. De Palma G, Lynch MD, Lu J, et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med 2017; 9 : eaaf6397. [Google Scholar]
  24. Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24 : 513–20-e246-7. [Google Scholar]
  25. Li G, Yang M, Jin Y, et al. Involvement of shared mucosal-associated microbiota in the duodenum and rectum in diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2018 ; 33 : 1220–1226. [Google Scholar]
  26. Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep 2015 ; 5 : 12693. [Google Scholar]
  27. Gargari G, Taverniti V, Gardana C, et al. Fecal clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol 2018 ; 20 : 3201–3213. [Google Scholar]
  28. Peleman C, Camilleri M, Busciglio I, et al. Colonic transit and bile acid synthesis or excretion in patients with irritable bowel syndrome-diarrhea without bile acid malabsorption. Clin Gastroenterol Hepatol 2017; 15 : 720–7e1. [Google Scholar]
  29. Zhan K, Zheng H, Li J, et al. Gut microbiota-bile acid crosstalk in diarrhea-irritable bowel syndrome. Biomed Res Int 2020; 2020 : 3828249. [Google Scholar]
  30. Li YJ, Li J, Dai C. The role of intestinal microbiota and mast cell in a rat model of visceral hypersensitivity. J Neurogastroenterol Motil 2020; 26 : 529–38. [Google Scholar]
  31. Gu X, Song LJ, Li LX, et al. Fusobacterium nucleatum causes microbial dysbiosis and exacerbates visceral hypersensitivity in a colonization-independent manner. Front Microbiol 2020; 11 : 1281. [Google Scholar]
  32. Bonfrate L, Di Palo DM, Celano G, et al. Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients. Eur J Clin Invest 2020; 50 : e13201. [Google Scholar]
  33. Laval L, Martin R, Natividad JN, et al. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2–165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes 2015 ; 6 : 1–9. [Google Scholar]
  34. Lopez-Siles M, Martinez-Medina M, Busquets D, et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes. Int J Med Microbiol 2014 ; 304 : 464–475. [Google Scholar]
  35. Salvo-Romero E, Martinez C, Lobo B, et al. Overexpression of corticotropin-releasing factor in intestinal mucosal eosinophils is associated with clinical severity in diarrhea-predominant irritable bowel syndrome. Sci Rep 2020; 10 : 20706. [Google Scholar]
  36. Chong PP, Chin VK, Looi CY, et al. The microbiome and irritable bowel syndrome - a review on the pathophysiology, current research and future therapy. Front Microbiol 2019 ; 10 : 1136. [Google Scholar]
  37. Shukla R, Ghoshal U, Ranjan P, Ghoshal UC. Expression of Toll-like receptors, pro-, and anti-inflammatory cytokines in relation to gut microbiota in irritable bowel syndrome: the evidence for its micro-organic basis. J Neurogastroenterol Motil 2018 ; 24 : 628–642. [Google Scholar]
  38. Zhen Y, Chu C, Zhou S, et al. Imbalance of tumor necrosis factor-alpha, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea. Mol Med Rep 2015 ; 12 : 5239–5245. [Google Scholar]
  39. Lacy B, Ayyagari R, Guerin A, et al. Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome. Therap Adv Gastroenterol 2019 ; 12 : 1756284818818326. [Google Scholar]
  40. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011 ; 364 : 22–32. [Google Scholar]
  41. Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut 2017 ; 66 : 1517–1527. [Google Scholar]
  42. Preston K, Krumian R, Hattner J, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes 2018 ; 9 : 697–706. [Google Scholar]
  43. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003 ; 17 : 895–904. [Google Scholar]
  44. Johnsen PH, Hilpusch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018 ; 3 : 17–24. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.